P3C

P3C is a peptide-based inhibitor of **farnesyl pyrophosphate synthase (FPPS)**, a key enzyme in the **mevalonate (MVA) pathway**. Developed as a potential therapeutic for **bone diseases** and **cancer** (specifically colorectal cancer), P3C was designed to overcome the limitations of traditional nitrogen-containing bisphosphonates (N-BPs), which have high bone affinity but poor penetration into soft tissues. P3C, often synthesized as a phosphopeptide, binds to the FPPS enzyme and inhibits its activity, thereby preventing the biosynthesis of isoprenoids like farnesyl pyrophosphate (FPP). This disruption prevents the post-translational **prenylation of small GTPases** (such as Ras, Rho, and Rab), which are essential for cell signaling, proliferation, and survival. In preclinical studies, P3C has demonstrated significant antiproliferative effects on murine colorectal cancer (CRC) cells and shows potential for modulating bone homeostasis by balancing osteoclast and osteoblast activity.

Other names

Peptide 3CPeptide3CPeptide-3CPhosphopeptide 3CPhosphopeptide3CPhosphopeptide-3C